Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

The firm’s stance comes amid expectations of profit growth pressure in 2025 due to Stelara-related headwinds ... part of the company’s business model. With an EBITDA of $385 million and ...

Johnson & Johnson (NYSE: JNJ) is set to report its first-quarter earnings on Tuesday, April 15th, before the market opens, ...

The longtime Oriole has been a huge part of the team's resurgence. But he's also a free agent-to-be with potential in-house ...

The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor calls. A critic of the “big 3” dismissed the statements as posturing.

J&J’s biggest strength is its diversified business model, which helps it to withstand ... for its multi-billion-dollar product Stelara, the negative impact of the Part D redesign and the greater ...